Saturday 17 October 2026
Export BDSX’s income statement to Excel — free account
Biodesix, Inc.
BDSX Healthcare Diagnostics & Research
Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024. In the quarter to June 2026, revenue grew 34.2%, EPS grew 55.6%, free cash flow grew 72.8% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
23.66
1.05
−4.25%
Follow BDSX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.71 | 0.58 | 1.46 | 2.26 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(6.38) | 66.00 | (13.77) | (148.64) | |
P/B ratio |
0.00 | 0.00 | 15.33 | 25.39 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.09 | 0.90 | 1.67 | 2.42 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.10) | (3.43) | (6.48) | (12.56) | |
EV/FCF |
(2.97) | (3.37) | (6.37) | (12.21) | |
Quick Ratio |
1.61 | 1.61 | 2.42 | 2.56 | |
Current Ratio |
1.84 | 1.87 | 2.82 | 2.85 | |
Net Debt/EBITDA |
(5.72) | (125.39) | (4.70) | (4.63) | |
Debt/Assets |
53.11% | 54.24% | 49.12% | 49.11% | |
Debt/Equity |
(27.36) | (19.25) | 5.09 | 5.12 | |
Asset Turnover |
0.84 | 0.96 | 1.06 | 1.12 | |
Operating CF/Net income |
1.02 | (0.20) | 1.30 | 0.21 | |
Capex/Depreciation |
(0.04) | (0.06) | (0.08) | (0.14) | |
Interest Coverage |
(3.40) | (0.96) | (3.14) | (2.72) | |
Research and Development Expense of Revenue |
13.74% | 9.98% | 12.85% | 11.67% | |
Selling, General and Administrative Expense of Revenue |
99.75% | 79.89% | 94.94% | 90.40% | |
Intangible Assets out of Total Assets |
0.22 | 0.22 | 0.20 | 0.19 | |
Share Based Compensation of Revenue |
4.84% | 3.74% | 4.36% | 3.05% | |
Graham Net Nets |
(1.01) | (1.12) | (0.32) | (0.18) | |
Graham Number |
5.36 | 5.97 | 0.00 | 0.00 | |
Earnings Yield |
(73.64%) | (71.32%) | (28.00%) | (14.06%) | |
Free Cash Flow Yield |
(51.79%) | (46.11%) | (18.03%) | (8.79%) | |
Revenue per Share |
2.90 | 3.81 | 2.65 | 2.61 | |
Operating CF per Share |
(1.18) | 0.10 | (1.05) | (0.15) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.02) | |
Free Cash Flow per Share |
(1.19) | 0.09 | (1.07) | (0.18) | |
Cash per Share |
2.21 | 2.51 | 2.65 | 2.91 | |
Shareholders Equity per Share |
(0.23) | (0.33) | 0.95 | 0.89 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.23) | (0.33) | 0.95 | 0.89 | |
Free Cash Flow |
(8.95) | 0.67 | (10.31) | (1.82) | |
Working Capital |
15.25 | 15.08 | 26.42 | 28.27 | |
Capital Expenditures |
(0.07) | (0.10) | (0.14) | (0.25) | |
Net Current Asset Value |
(57.04) | (57.42) | (44.59) | (42.62) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.36 | 8.82 | 8.57 | 8.28 | |
Average Payables |
3.08 | 2.64 | 3.29 | 2.57 | |
Average Assets |
95.73 | 92.36 | 90.44 | 91.53 | |
Average Common Equity |
13.07 | 9.21 | 10.10 | 5.14 |
Columns are period end dates